RxDoctor Payments Data

Jorge Ortega Gil, MD

Cardiovascular Disease · Rio Piedras, PRNPI 1154468239

Payments from drug & device makers

$987in general payments, 2019–2025

Across 45 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$445
  • Boston Scientific$165
  • E.r. Squibb & Sons, L.L.C.$95
  • Johnson & Johnson$79
  • Boehringer Ingelheim$55
  • Novartis$49
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$987 in reported general payments places this provider in the 25th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,284
Medicare patients
16
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin48$34,366
EliquisApixaban30$21,853
EntrestoSacubitril/Valsartan30$20,115
XareltoRivaroxaban14$11,088
FarxigaDapagliflozin Propanediol11$8,870
SynthroidLevothyroxine Sodium34$2,670
Metoprolol Succinate141$1,302
Atorvastatin Calcium165$1,261
Chlorthalidone58$970
Losartan Potassium64$569
Candesartan Cilexetil12$533
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide32$530
Mirtazapine11$505
Enalapril Maleate21$497
Tamsulosin Hcl15$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$55$34,36648 claims
NovartisEntresto$49$20,11530 claims
Johnson & JohnsonXarelto$79$11,08814 claims
AstraZenecaFarxiga$13$8,87011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →